Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Zale Corporation (ZLC),, inc. (CRM), Astex Pharmaceuticals, Inc. (ASTX): Five of Last Week’s Biggest Winners

What’s better than momentum? Mo’ momentum. Let’s take a closer look at five of this past week’s biggest scorchers.

Company Aug. 30 Weekly Gain
Zale Corporation (NYSE:ZLC $12.51 39%
K12 Inc. (NYSE:LRN) $36.31 16%, inc. (NYSE:CRM) $49.13 13%
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) $6.55 11%
Splunk Inc (NASDAQ:SPLK) $55.21 10%

Source: Barron’s.

Let’s start with Zale Corporation (NYSE:ZLC). The high-end jeweler soared after coming through with a strong quarter. There was an unexpectedly strong 5.6% boost to Zale Corporation (NYSE:ZLC)’s comps, and even though it did post a loss, it was a lot less than what the pros were targeting. This isn’t a seasonally potent period for jewelry sales, anyway, but the healthy pop in same-store sales is the stylish kind of bling that never goes out of fashion.

K12 Inc. (NYSE:LRN) moved to the head of the class after its better-than-expected fourth-quarter results. Revenue climbed 19% to $203.1 million, fueled by a 21% spike in its managed public schools business. The provider of online education solutions earned $0.06 a share. Wall Street was banking on only half that much., inc. (NYSE:CRM)

K12 came under fire last year with questions about the effectiveness of virtual classrooms at the grade level, but enrollments aren’t slowing. The company has seen its student base grow by 13% over the past year.

It was another week of new highs for, inc. (NYSE:CRM), as the cloud-based enterprise-software giant served up a blowout quarter., inc. (NYSE:CRM) has been able to grow quickly as it offers businesses cost-effective software solutions. Revenue clocked in 31% higher in its latest quarter.

Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) moved higher after receiving encouraging top-line data in a midstage trial for a treatment tackling acute myeloid leukemia. The treatment’s overall remission rate was positive in the study of 67 patients. The path to take a drug candidate to market is a long one, but Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) has seven different clinical trials going on at the moment.

Finally, we have Splunk Inc (NASDAQ:SPLK) proving that there are big gains in Big Data. Splunk reported a 50% revenue surge, well ahead of its earlier projections and Wall Street expectations. Its adjusted deficit of $0.01 a share was also better than analysts were forecasting.

A beat these days isn’t enough to move a stock higher, and that’s why it’s comforting to see Splunk raising its top-line guidance for the entire year. It now sees $275 million to $281 million in revenue, well ahead of its earlier $266 million to $274 million range.

The article 5 of Last Week’s Biggest Winners originally appeared on and is written by Rick Munarriz.

Longtime Fool contributor Rick Munarriz has no position in any stocks mentioned. The Motley Fool recommends K12 and

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.